Open access peer-reviewed chapter

Thrombosis, Atherosclerosis and Atherothrombosis – New Insights and Experimental Protocols

Written By

Jasmina Dimitrova-Shumkovska, Leo Veenman, Inbar Roim, Svetlana Leschiner and Moshe Gavish

Submitted: March 16th, 2015 Reviewed: November 9th, 2015 Published: December 2nd, 2015

DOI: 10.5772/61971

Chapter metrics overview

1,375 Chapter Downloads

View Full Metrics


Previous studies have shown that TSPO as well as apolipoprotein E (Apo E) can be associated with processes such as cholesterol metabolism, oxidative stress, apoptosis, glial activation, inflammation, and immune responses. As a ligand for cell-surface lipoprotein receptors, apolipoprotein E can prevent atherosclerosis by clearing cholesterol-rich lipoproteins from plasma. Furthermore, TSPO takes part in the regulation of gene expression for proteins involved in adhesion, which potentially may play a role in platelet aggregation. There are indications that the Apo E protein is involve in platelet aggregation, while TSPO platelet levels have been found to be increased with various neurological disorders, in particular, in stress-related disorders. The role of platelets in atherogenesis and the potential therapeutic impact of TSPO ligands on disease prevention are of great interest. To determine TSPO binding characteristics in this paradigm, we applied binding assays with [3H]PK 11195 on isolated platelets and erythrocyte membranes. The in vivo findings in Apo E knockout mice revealed that TSPO levels appear to be enhanced in platelets and erythrocytes of Apo E knockout mice, and thus suggest that TSPO and Apo E expression may be interconnected in relation to some aspect of the host defense response. Other organs tested, such as liver, testis, brain, heart, aorta, lung, kidney and spleen, did not show a difference in TSPO binding levels between Apo E knockout mice and wild-type mice. This suggests that TSPO levels may be part of a feedback control system for steroid production (responding to alterations in steroid levels), rather than being regulated by a feed-forward signal provided by cholesterol (i.e. TSPO levels in relation to steroidogenesis are not being regulated by cholesterol levels in vivo).


  • Dyslipidemia
  • Platelets
  • Translocator protein
  • Erythrocytes
  • Apo E-KO mice

1. Introduction

1.1. The connection of apolipopoprotein E and platelet activation to inflammation and atherosclerosis

Atherosclerosis is a chronic inflammatory disease of the arteries of multifactorial etiology that involves a complex interaction among oxidized lipids, plasma proteins, vascular endothelial and smooth muscle cells and platelets [13]. Hypercholesterolemia and especially high concentrations of low-density lipoproteins (LDL) are significant factors for the premature development of atherosclerotic plaque. In parallel, elevated LDL levels exert prothrombotic effects via platelet activation [4].

Dysfunction or low levels of platelets predispose to bleeding, while high levels, although usually asymptomatic, may increase the risk of thrombosis, thus relating to atherosclerosis and Apo E malfunction [5]. Studies from Kolodgie et al. demonstrated that platelets and erythrocytes can penetrate the plaque through angiogenic capillary breakages [6]. Furthermore, platelets with their pro-atherogenic potential are regarded as discrete immune cells [7, 8]. They can accumulate lipids in the hypercholesterolemic environment and are involved in the early phase of atheromatous formation [9]. Oxidized low-density lipoproteins (ox-LDLs) are suggested to be implicated in the early phase of atherosclerosis by recruiting inflammatory cells in the subendothelium that elucidate the thrombotic process [10]. Several cells including endothelial cells, macrophages and smooth muscle cells determine ox-LDL formation. In vitro studies have shown that ox-LDL binds to platelets via CD36 and lectin-like endothelial receptor for ox-LDL (LOX-1 receptors), promoting platelet activation [11, 12]. Experimental studies demonstrated a marked reduction of thrombus formation in animals with the deletion of ox-LDL receptor CD36 from platelets [13]. In accordance with a number of in vitro results, in vivo LOX-1 expression, was not only upregulated under the influence of proinflammatory stimulus but also induced in adipose tissue after high-fat diet feeding, suggesting that increased LOX-1 expression may promote atherosclerosis [14, 15].

Apolipoprotein E functions as an important carrier protein in the redistribution of lipids among cells, by incorporating into high-density lipoproteins (as HDL-E), and plays a prominent role in the transport (by incorporating into intestinally synthesized chylomicrons) and metabolism of plasma cholesterol and triglyceride through its ability to interact with the LDLR and the receptor binding of Apo E lipoproteins (apoER) [16, 17]. The metabolic activity of Apo E is sensitive to its lipid environment; purified Apo E does not interact with the LDLR [18]. Apo E at the surfaces of VLDL and chylomicrons is also inactive unless these lipoproteins are from hypertriglyceridemic subjects [19] or have undergone substantial lipolysis to form remnant particles [20]. Apo E is part of different metabolic pathways in the body. One of these pathways is endocrine-like, and involves the redistribution of lipids among cells of different organs. It takes lipids from the areas where the lipid is synthesized and distributes them to other areas where the lipids are used or stored. Another pathway is paracrine-like, where the lipids are transported among cells in the same organ or tissue. Since Apo E is involved directly in the uptake and distribution of plasma lipids, it is natural that it has several implications for cardiovascular disease. Interestingly, oxLDL as a ligand for LOX-1 is highly present in circulation and lesion formation in atherosclerotic prone animals, such as Apo E KO mice.

The Apo E is also involved in various pathways that are unrelated to lipid transport, such as the stimulation of lymphocytes and macrophage secretion [21]. This appears important for facilitating local cholesterol redistribution and for reverse cholesterol transport [22]. As a ligand for cell surface lipoprotein receptors, apolipoprotein E can prevent atherosclerosis by clearing cholesterol-rich lipoproteins from plasma. Indeed, atherosclerosis in Apo E-deficient (Apo E2/2) mice can be prevented by transplantation of normal murine bone marrow cells [23], by macrophage-specific expression of the human Apo E transgene [24], or by adenovirus-mediated gene replacement [25]. It was also found that altered Apo E expression leads to enhanced inflammation responses [2628].

Defects in Apo E sometimes result in its inability to bind to the LDL receptors, which leads to an increase in a person's blood cholesterol. Recently, it has been suggested that high cholesterol levels due to Apo E malfunction may constitute a risk factor for Alzheimer’s disease [29, 30]. According to the expressed isoforms, Apo E might be involved (i) in maintaining the integrity of the aging CNS [31]; (ii) in repair, growth and maintenance of myelin and axonal membranes during development and after an injury [32]; (iii) in neurite outgrowth [33]; (iv) in neurotoxicity [34]; and (v) in pathological processes in general, including Alzheimer's disease [35].

Riddell’s study found that HDL-E was a powerful inhibitor of agonist-induced platelet aggregation, through interaction with saturable binding sites in the platelet surface membrane, which further suggested that Apo E exerts its antiplatelet aggregation effect via L-arginine: nitric oxide pathway by enhancing the production of endogenous nitric oxide (NO) [36]. Calcium is central to the control of platelet reactivity, interacting with diverse second messengers through a myriad of complex but tightly regulated, signalling pathways [37]. Two important control elements for suppression of platelet activation are the cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and agents that increase their intraplatelet levels exert antiaggregatory effects both in vitro and in vivo [38]. Although Apo E induced increases in both cAMP and cGMP, additional experiments implicated a specific stimulation of guanylate cyclase activity and a rise in cGMP as prerequisites for the antiplatelet action of Apo E. Using the L-arginine:nitric oxide pathway, the vascular endothelium synthesizes NO from the terminal guanidine nitrogen atoms of L-arginine using a soluble enzyme called NO synthase (NOS). NO then binds to soluble guanylate cyclase to produce cGMP, which has inhibitory effects on platelet aggregation. The increased levels of cGMP also decrease the amount of cAMP phosphodiesterase, the enzyme that converts cAMP to AMP. The decrease in cAMP phosphodiesterase causes an increase in cAMP, and cAMP also has an inhibitory effect on platelet aggregation [10, 36].

1.2. Potential functional commonalities between apolipoprotein E and 18 kDa translocator protein

It was shown previously that the 18 kDa translocator protein (TSPO) is present throughout the cardiovascular system and may be involved in cardiovascular disorders such as ischemia [36]. At cellular levels, TSPO is present in virtually all of the cells of the cardiovascular system, where they appear to take part in the responses to various challenges that an organism and its cardiovascular system face, including atherosclerosis and accompanying symptoms [22, 3942].

The TSPO was previously known as peripheral type benzodiazepine receptor (PBR), since it is capable of binding benzodiazepines and is found in most if not all peripheral tissues [43]. Mitochondrial membranes form the primary location for TSPO [44]. It is an integral membrane protein that interacts with a wide variety of endogenous ligands, such as cholesterol and porphyrins, and is also a target for several small molecules with substantial in vivo efficacy. When complexed with the TSPO-specific radioligand PK11195, TSPO folds into a rigid five-helix bundle.

TSPO are present in platelets, lymphocytes and mononuclear cells and are also found in the endothelium, the striated cardiac muscle, the vascular smooth muscles and the mast cells of the cardiovascular system. As TSPO is known to regulate heme metabolism, TSPO may play essential roles in erythrocyte function [45]. TSPO in the cardiovascular system also appears to play roles in several aspects of the immune response, such as phagocytosis and the secretion of interleukin-2, interleukin-3 and immunoglobulin A [46]. Mast cells are considered to be important for immune response to pathogens [47], and they have also been implicated in the regulation of thrombosis and inflammation and cardiovascular disease processes such as atherosclerosis as well as in neoplastic conditions [48]. Benzodiazepines have been found to bind to specific receptors on macrophages and to modulate in vitro their metabolic oxidative responsiveness [49]. Haemin, isolated from human erythrocytes, competitively inhibits mitochondrial benzodiazepine binding with a Ki of 41 nM [50]. The TSPO might present a therapeutic target for arrhythmia, myocardial infarction and cardiac hypertrophy by reducing ROS. For example, the suppression of TSPO can prevent caspase cascade activation and cytochrome c release, thus inhibiting ROS overload [5, 5160]. The results from several in vitro studies have implicated TSPO in cholesterol transport into mitochondria, the late-limiting step in the steroid biosynthesis. Therefore, TSPO has been considered as a critical factor in steroidogenesis. Moreover, the ubiquitous expression and evolutionary conservation of TSPO from bacteria to mammals strongly suggested its essential role in cellular processes. This presumption was further supported by the results of an earlier study that claimed the embryonic lethality of TSPO whole-body knockout (KO) mice, although the details of the methods for the design and generation of the KO mice were not provided [52, 53].

A scheme of the involvement of mitochondrial TSPO in various cellular functions and disease is given in Figure 1. For detailed discussions regarding these functional pathways, see refs. [49] and [58].

Figure 1.

The 18 kDa mitochondrial translocator protein (TSPO) in relation to cellular function and disease.

TSPO molecules are often found in groups and in conjugation with VDAC and ANT. As indicated in the figure, pk10, PRAX-1 and PAP7 face the cytosol. Furthermore, molecules of the Bcl-2 family and creatine kinase and hexokinase can be attached to VDAC and ANT. Various synthetic ligands that bind to TSPO have been developed. Endogenous ligands that bind to TSPO include: protoporphyrin IX, DBI and its fragment TTN and PLA2. The TSPO is involved in various functions as indicated towards the bottom of the figure. Abbreviations: ANT, adenine nucleotide transporter; ATP, adenosine triphosphate; DBI, diazepam-binding inhibitor; PAP7, PBR-associated protein 7; PBR, peripheral-type benzodiazepine receptor; pk10, protein of 10 kilodalton; PLA2, phospholipase A2; PRAX-1, PBR-associated protein 1; TSPO, translocator protein (18 kDa); TTN, triakontatetraneuropeptide; VDAC, voltage-dependent anion channel.

Recently, it was shown that TSPO ligands specifically designed for this purpose can increase lifespan in animal models for human disease [61]. For example, the occurrence of cardiac arrest, the typical cause of death in R6-2 mice, is delayed considerably in this animal model for Huntington disease [62]. In numbers, average lifespan is increased from ±12 weeks to ±15 weeks. Translated to the human situation, this would mean in simple terms that life expectancy of Huntington disease patients can potentially be increased from an average of 60 years to an average of 85 years following treatments with the appropriate TSPO ligands. Such TSPO ligands were also shown to prevent and counteract brain edema associated with seizures developed after systemic injections of kainic acid in rats [61, 62].

Anti-inflammatory properties of TSPO ligands have also been demonstrated in nonneuronal tissues [63]. TSPO ligands have been shown to reduce inflammation in animal models of rheumatoid arthritis [59], carrageenan-induced pleurisy [64] and pulmonary inflammation [65]. A summary of the involvement of TSPO and apoE in functions common to both as suggested by previous studies discussed above is presented in Figure 2. Therefore, we studied whether knockout of apolipoprotein E in mice may have an effect on TSPO expression in platelets and erythrocytes. This could suggest that TSPO is involved in the regulation of functions under the control of ApoE as mentioned in Figure 2.

Figure 2.

Possible correlations between Apo E and TSPO due to potential participation in various functions.


2. Materials and methods

Apolipoprotein E–deficient mice (Apo E KO mice) present a well-established model to study atherogenesis. In these mice, reverse cholesterol transport is dysfunctional, increasing the blood cholesterol level up to five times higher than in normal mice [66]. As Apo E deficiency causes increased cholesterol levels, which in turn may modulate TSPO function, we were interested to study whether TSPO binding characteristics may be affected in erythrocyte and platelet membranes. For this purpose, we used 12- to 14-week-old healthy male C57BL/6 mice (i.e. wild type, WT) and 14-week-old Apo E knockout (KO) mice. The mice were housed in polycarbonate cages in a pathogen-free facility set on a 12-h light–dark cycle and given ad libitum access to water and standard laboratory feed. All experimental procedures were carried out following the guidelines of the International European ethical standards for the care and use of laboratory animals (Community Council Directive 86-609). All protocols were approved and reviewed by the local ethics committee.

Platelets and erythrocytes preparation. Up to 1 mL of mouse blood was drawn by cardiac puncture of deeply anesthetized fasting mice in a terminal procedure and collected in plastic tubes containing trisodium citrate [3/8%, 1/10 (v:v)].

Platelet preparation

  1. To obtain platelet-rich plasma (PRP), blood was centrifuged at 200×g for 20 min

  2. Then, 3/4 of the supernatant was collected to a new tube and centrifuged at 1000×g for 30 min

  3. The pellet was washed with Tyrode’s buffer (Sigma-Aldrich, T1788) in a volume identical to the volume of the original fluid and centrifuged at 1000×g for 15 min and the pellet that contained only platelets was used for binding assay

Erythrocyte preparation

  1. The pellet obtained from the first centrifugation (protocol i) at 200×g, was washed three times in isotonic solution of sodium chloride and used for isolation of erythrocyte membranes

  2. Purified erythrocytes were suspended in a 30-fold volume of 20 mM PBS containing 1 mM MgCl2, pH 7.5, allowed to stand for one hour prior to centrifugation at 13,000×g, 40 min at 4°C, in order to obtain erythrocyte membrane as pellet [67]

  3. Protein concentration of membrane preparations were determined by the Bradford assay [68, 69]

Assays of TSPO binding characteristics by [3H]PK 11195 binding measurements. Maximal binding capacity (Bmax) and equilibrium dissociation constant (Kd) of the binding of the TSPO-specific ligand, [3H]PK 11195, in whole cell membrane preparations from the platelets and erythrocytes were assayed as described previously [40, 70, 71]. [3H]PK 11195 (1-(2-chlorphenyl)-N-methyl-N-(1-methypropyl)-3-isoquinolinecarboxamide) was obtained from New England Nuclear (Boston, MA). Unlabeled PK 11195 was purchased from Sigma-Aldrich, Israel (Rehovot, Israel).


  • For binding assays of the Bmax and the Kd, the reaction mixtures contained 400 µL of the membrane preparation in question (≈100 µg protein) and 25 µL of [3H]PK 11195 solution (0.2 to 6 nM final concentrations) in the absence (total binding) or presence (nonspecific binding) of 75 µL unlabeled PK 11195 (10 µM final concentration)

  • After incubation for 90 min in ice-water bath, the samples were vacuum filtered through Whatman GF/C filters, washed three times with 4 mL of 50 mM phosphate buffer and placed in vials containing 4 mL of Opti-Fluor (Waltham, MA)

  • Radioactivity was counted after 12 h with a 1600CA Tri-Carb liquid scintillation analyser (Packard, Meriden, CT). Scatchard analysis of [3H]PK 11195 binding was done to determine the Bmax and Kd values

  • For one point binding analysis, the concentration of 6 nM [3H] PK 11195 was applied

The Bradford assay is based on the equilibrium between three forms of Coomassie blue G dye. Under strong acidic conditions, the dye is stable as a doubly protonated red form. Upon binding to protein, it is most stable as an unprotonated, blue form. Determination of microgram quantities of protein in the Bradford Coomassie brilliant blue assay is established by measurement of absorbance at 590 nm [69]. For this protein assay, Bradford solution (comprising Coomassie Brilliant Blue G-250 and an acid with a pKa of 1–2) was obtained from Bio-Rad (Munich, Germany).


  • 10 µL from each sample was mixed with 200 µL of Bradford solution in 96-well plates, and incubated for 10 min in the dark at room temperature

  • Absorption was measured using an ELISA Reader or “ULTRASPECTRO 2000” at 595 nm. The protein concentration was determined by comparing the absorption values of the protein samples to the appropriate BSA standard curve, prepared from the BSA volumes: 0, 2, 4, 8, 10, 15, 20, 25, 50, 100 and 150 μL, completed to a final volume of 800 μL by DDW


3. Results with discussion

Atherosclerosis is characterized by inflammatory infiltration into the arterial wall of macrophages, dendritic cells, platelets and activated T cells, resulting in plaque formation. This process is initiated by inappropriate lipid metabolism, calcium signaling and increased burden of secretory pathways [3]. Macrophages, especially in the atherosclerotic plaque, contribute to the local inflammatory responses by secreting proinflammatory cytokines [72]. Activated macrophages have been demonstrated with high TSPO expression levels [73, 74]. TSPO has been identified in human leukocytes and erythrocytes and appears to play roles in several aspects of the immune response and the regulation of the host defense response in general [43, 46]. In addition, TSPO was detected in the plasma membrane of neutrophils, where it was shown to stimulate adhesion and motility [75].

Apolipoprotein E may also be involved in the immune response, as suggested by the impaired immune response in Apo E-deficient mice [76]. TSPO levels in platelets of rats and humans have been demonstrated to respond to a wide variety of pathological conditions [46, 77, 78]. It has been suggested that TSPO density in platelets can be used as a promising biological marker of stressful conditions [7981].

To determine TSPO binding characteristics in Apo E-KO mice, we applied binding assays with the TSPO-specific ligand [3H] PK 11195. Since cholesterol plays an important role in steroidogenesis, atherosclerosis and Alzheimer’s disease, which have been correlated with TSPO and Apo E expression, we expected to find changes in TSPO binding levels in platelets and erythrocytes of Apo E-knockout mice compared to their WT strain. Indeed, regarding the platelets and erythrocytes, a significant increase (p < 0.05) in TSPO binding was noticed in Apo E knockout mice compared to WT (Table 1). In addition, our results showed no major difference in TSPO Bmax between WT and Apo E-KO mice in other tissues (data not shown); suggesting that the effects seen on platelets and erythrocytes may be quite specific in relation to atherosclerosis.

Scatchard analysis demonstrates [3H]PK 11195 binding of 1923 ± 1010 fmol/mg protein in erythrocyte membranes of wild-type mice vs. 3142 ± 1761 fmol/mg measured in erythrocytes membranes in the Apo E KO group (Figure 2). The obtained results from erythrocytes' membranes in our study are in the range of those in human membranes as measured by Olson et al. [67]. In these human erythrocytes, the Bmax was 1120 fmol/mg protein and the Kd 3.9 ± 0.4 nM. It has been suggested that TSPO present in the plasma membrane of erythrocytes is involved in redistribution of intracellular cholesterol to change the nuclear membrane rigidity prior to erythrocyte maturation [82]. Recent studies by us have shown that TSPO is involved in the regulation of gene expression as well as heme metabolism [45, 83, 84]. More studies may provide deeper insights into how TSPO is involved in molecular biological mechanisms and biological functions of erythrocytes.

Table 1.

[3H] PK 11195 binding parameters in mice erythrocyte and platelet membranes

Average B values fmoles/mg protein and Kd values (nM) of 6 nM [3H]PK 11195 binding to TSPO in erythrocyte and platelets membranes of WT (Bb-Control) and Apo E KO mice, fed with standard feed. One-way analysis of variance ANOVA was used, with Mann–Whitney as the post hoc, nonparametric test. Data are expressed as mean ± SD; *, p < 0.05; **, p < 0.01, vs. control.

Activated platelets are detected in increased numbers in the circulation of patients with atherosclerosis, coronary artery disease, and hypercholesterolemia. In the advanced atherosclerosis model of Apo E KO mice, subendothelial infiltration of monocytes/macrophages and platelets was observed, suggesting intimate interactions of platelets and macrophages in early atherosclerosis [85]. A recent paper by Nishikawa et al. demonstrated the role of hydrogen sulfide (H2S), a gasotransmitter, in inhibiting platelet aggregation by interfering the cytosolic Ca2+ mobilization in a cAMP-dependent manner, comparable to what is observed for nitric oxide (NO) [86]. Studies by us have suggested that functions regulated by NO require the presence and activation of TSPO [87]. A study from Hamilton et al. indicated that activation of platelets with thrombin and other agents can promote atherogenesis [2]. Activation of human platelets is inhibited by two intracellular pathways regulated by either cyclic AMP or cyclic GMP. The importance of cyclic second messengers in modulating platelet reactivity is well established, elaborating the lipid-lowering effects of simvastatin therapy on inhibition of platelet aggregation through increasing the levels of both cAMP and cGMP [4]. Although Apo E induced increases in both cAMP and cGMP, additional experiments implicated a specific stimulation of guanylate cyclase activity and a rise in cGMP as prerequisites for the inhibitory effects on platelet aggregation of Apo E. Nonetheless, the mechanisms by which platelets promote atherogenesis need further observations.

Figure 3.

Representative examples of Scatchard plots of saturation curves of [3H] PK 11195 binding to membrane preparations of platelets of wild-type mice (A) and apo E-KO mice (B). Abbreviations: B, bound; B/F, bound over free.

Both TSPO and Apo E have been found to be involved in neurodegeneration. Both molecules have been associated with particular common factors being part of neurodegenerative diseases, such as cholesterol metabolism, oxidative stress, apoptosis and inflammation (Figure 1). Furthermore, Apo E was found to be involved in platelet aggregation, while TSPO expression in platelets has been associated with various pathological conditions, including neurological disorders [46]. Some authors have reported the protective effects of TSPO agonists in experimental neuropathy, suggesting reparative actions of brain TSPO in such a disease [88]. A recent study from Giannaccini et al. demonstrated upregulated TSPO expression in the brain region of leptin-deficient obese mice (ob/ob) [89]. In addition, the induction of TSPO expression under neuropathological conditions suggests that this molecule may be involved in the response of the neural tissue to inflammation [90, 91]. Indeed, application of TSPO ligands can dramatically decrease neuropathological symptoms of various diseases and injuries [61, 62]. However, the precise role of TSPO in the injured neural tissue needs to be investigated further.

In conclusion, the platelets' and erythrocytes' constant exposure to enhanced levels of cholesterol in the bloodstream may be associated with increased TSPO levels. One mechanism may be that apoE's modulation of NO levels may affect TSPO expression in the platelets and erythrocytes. Our study indicates that the Apo E mouse presents a promising animal model to elucidate the exact role of TSPO in platelets and erythrocytes in a cholesterol-dependent atherosclerosis. Thus, the TSPO represent a novel therapeutic target and diagnostic tool for cardiovascular disease and its complications.

Explanation of abbreviations and symbols: ANOVA, analysis of variance; ApoE–/– KO, apolipoprotein E knockout mice; ApoER, apolipoprotein E receptor; BSA, bovine serum albumin; cAMP, adenosine 3,5-cyclic monophosphate; DBI, diazepam binding inhibitor; CAM, cell adhesion molecule; Er, erythrocytes; H2S, hydrogen sulfide; HDL, high-density lipoprotein; kDa, kilodalton; Kd, equilibrium dissociation constant; Km, equilibrium constant related to Michaelis–Menten kinetics (similarly, Kd, Ka, Keq, Ks); LDL, low-density lipoproteins; LDLR, low-density lipoprotein receptor; LOX-1, the lectin-like endothelial receptor for ox-LDL; mPTP, mitochondrial permeability transition pore; MCP-1, monocyte chemoattractant protein-1; NADP, nicotinamide adenine dinucleotide phosphate; NADH, reduced nicotinamide adenine dinucleotide; NO, nitric oxide; NOS, nitric oxide synthase; ox-LDL, oxidized low-density lipoproteins; PBR, peripheral-type benzodiazepine receptor; PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methyl-prop1)-3 isoquinoline carboxamide; ROS, reactive oxygen species; TSPO, 18 kDa translocator protein.


  1. 1. Camici PG, Rimoldi OE, Gaemperli O, Libby P. Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque. Eur Heart J 2012; 33:1309–1317.
  2. 2. Hamilton JR, Cornelissen I, Mountford JK, Coughlin SR. Atherosclerosis proceeds independently of thrombin-induced platelet activation in ApoE–/– mice. Atherosclerosis 2009; 205:427–432.
  3. 3. Li H, Horke S, Forstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014; 237:208–219.
  4. 4. Lee YM, Chen WF, Chou DS, et al. Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation. J Biomed Sci 2010; 17:45.
  5. 5. West LE, Steiner T, Judge HM, Francis SE, Storey RF. Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovasc Res 2014; 102:429–435.
  6. 6. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349:2316–2325.
  7. 7. Bultmann A, Li Z, Wagner S, et al. Impact of glycoprotein VI and platelet adhesion on atherosclerosis—a possible role of fibronectin. J Mol Cell Cardiol 2010; 49:532–542.
  8. 8. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196:887–896.
  9. 9. Gonzalez J, Donoso W, Diaz N, et al. High fat diet induces adhesion of platelets to endothelium in two models of dyslipidemia. J Obes 2014; 2014:591270.
  10. 10. Carnevale R, Bartimoccia S, Nocella C, et al. LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism. Atherosclerosis 2014; 237:108–116.
  11. 11. Chen Y, Cai T, Wang H, et al. Regulation of intracellular cholesterol distribution by Na/K-ATPase. J Biol Chem 2009; 284:14881–14890.
  12. 12. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
  13. 13. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007; 13:1086–1095.
  14. 14. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013; 2013:152786.
  15. 15. Yoshimoto R, Fujita Y, Kakino A, Iwamoto S, Takaya T, Sawamura T. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 2011; 25:379–391.
  16. 16. Elliott DA, Kim WS, Jans DA, Garner B. Macrophage apolipoprotein-E knockdown modulates caspase-3 activation without altering sensitivity to apoptosis. Biochim Biophys Acta 2008; 1780:145–153.
  17. 17. Quinn CM, Kagedal K, Terman A, et al. Induction of fibroblast apolipoprotein E expression during apoptosis, starvation-induced growth arrest and mitosis. Biochem J 2004; 378:753–761.
  18. 18. Mahley RW, Weisgraber KH, Innerarity TL. Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta 1979; 575:81–91.
  19. 19. Gianturco SH, Gotto AM, Jr., Hwang SL, et al. Apolipoprotein E mediates uptake of Sf 100–400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. J Biol Chem 1983; 258:4526–4533.
  20. 20. Hussain MM, Mahley RW, Boyles JK, Fainaru M, Brecht WJ, Lindquist PA. Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits. Factors that modify tissue-specific uptake. J Biol Chem 1989; 264:9571–9582.
  21. 21. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622–630.
  22. 22. Bird JL, Izquierdo-Garcia D, Davies JR, et al. Evaluation of translocator protein quantification as a tool for characterising macrophage burden in human carotid atherosclerosis. Atherosclerosis 2010; 210:388–391.
  23. 23. Linton MF, Fazio S. Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. Curr Opin Lipidol 1999; 10:97–105.
  24. 24. Bellosta S, Nathan BP, Orth M, Dong LM, Mahley RW, Pitas RE. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem 1995; 270:27063–27071.
  25. 25. Kashyap VS, Santamarina-Fojo S, Brown DR, et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest 1995; 96:1612–1620.
  26. 26. Hansson GK, Edfeldt K. Toll to be paid at the gateway to the vessel wall. Arterioscler Thromb Vasc Biol 2005; 25:1085–1087.
  27. 27. Ophir G, Amariglio N, Jacob-Hirsch J, Elkon R, Rechavi G, Michaelson DM. Apolipoprotein E4 enhances brain inflammation by modulation of the NF-kappaB signaling cascade. Neurobiol Dis 2005; 20:709–718.
  28. 28. Zeiffer U, Schober A, Lietz M, et al. Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. Circ Res 2004; 94:776–784.
  29. 29. Sjogren M, Blennow K. The link between cholesterol and Alzheimer's disease. World J Biol Psychiatry 2005; 6:85–97.
  30. 30. Wang ZY, Miki T, Ding Y, et al. A high cholesterol diet given to apolipoprotein E-knockout mice has a differential effect on the various neurotrophin systems in the hippocampus. Metab Brain Dis 2011; 26:185–194.
  31. 31. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 1995; 136:107–122.
  32. 32. Poirier J. Apolipoprotein E in the brain and its role in Alzheimer's disease. J Psychiatry Neurosci 1996; 21:128–134.
  33. 33. DeMattos RB, Curtiss LK, Williams DL. A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J Biol Chem 1998; 273:4206–4212.
  34. 34. Marques MA, Tolar M, Harmony JA, Crutcher KA. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport 1996; 7:2529–2532.
  35. 35. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:1977–1981.
  36. 36. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. J Biol Chem 1997; 272:89–95.
  37. 37. Heemskerk JW, Sage SO. Calcium signalling in platelets and other cells. Platelets 1994; 5:295–316.
  38. 38. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost 2012; 10:167–176.
  39. 39. Dimitrova-Shumkovska J, Veenman L, Gavish M, The 18 kDa translocator protein as a potential participant in atherosclerosis, In “Atherogenesis”: edited by Pathasarathy, S., ISBN 978-953-307-992-9, INTECH, 2012.
  40. 40. Dimitrova-Shumkovska J, Veenman L, Ristoski T, Leschiner S, Gavish M. Chronic high fat, high cholesterol supplementation decreases 18 kDa translocator protein binding capacity in association with increased oxidative stress in rat liver and aorta. Food Chem Toxicol 2010; 48:910–921.
  41. 41. Dimitrova-Shumkovska J, Veenman L, Roim I, Gavish M, The 18 kDa translocator protein and atherosclerosis in mice lacking apolipoprotein E, In “Lipid Metabolism”: edited by Baez RV, ISBN 978-953-51-0944-0, INTECH, 2013: 91–118.
  42. 42. Onyimba JA, Coronado MJ, Garton AE, et al. The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice. Biol Sex Differ 2011; 2:2.
  43. 43. Veenman L, Papadopoulos V, Gavish M. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des 2007; 13:2385–2405.
  44. 44. Anholt RR, De Souza EB, Kuhar MJ, Snyder SH. Depletion of peripheral-type benzodiazepine receptors after hypophysectomy in rat adrenal gland and testis. Eur J Pharmacol 1985; 110:41–46.
  45. 45. Zeno S, Veenman L, Katz Y, Bode J, Gavish M, Zaaroor M. The 18 kDa mitochondrial translocator protein (TSPO) prevents accumulation of protoporphyrin IX. Involvement of reactive oxygen species (ROS). Curr Mol Med 2012; 12:494–501.
  46. 46. Veenman L, Gavish M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol Ther 2006; 110:503–524.
  47. 47. Marshall JS, Jawdat DM. Mast cells in innate immunity. J Allergy Clin Immunol 2004; 114:21–27.
  48. 48. Wojta J, Huber K, Valent P. New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. Pathophysiol Haemost Thromb 2003; 33:438–441.
  49. 49. Lenfant M, Zavala F, Haumont J, Potier P. [Presence of a peripheral type benzodiazepine binding site on the macrophage; its possible role in immunomodulation]. C R Acad Sci III 1985; 300:309–314.
  50. 50. Verma A, Nye JS, Snyder SH. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc Natl Acad Sci U S A 1987; 84:2256–2260.
  51. 51. Caballero B, Veenman L, Gavish M. Role of mitochondrial translocator protein (18 kDa) on mitochondrial- related cell death processes. Recent Pat Endocr Metab Immune Drug Discov 2013; 7:86–101.
  52. 52. Jaremko L, Jaremko M, Giller K, Becker S, Zweckstetter M. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science 2014; 343:1363–1366.
  53. 53. Kim EJ, Yu SW. Translocator protein 18 kDa (TSPO): old dogma, new mice, new structure, and new questions for neuroprotection. Neural Regen Res 2015; 10:878–880.
  54. 54. Kugler W, Veenman L, Shandalov Y, et al. Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine. Cell Oncol 2008; 30:435–450.
  55. 55. Levin E, Premkumar A, Veenman L, et al. The peripheral-type benzodiazepine receptor and tumorigenicity: isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line. Biochemistry 2005; 44:9924–9935.
  56. 56. Midzak A, Akula N, Lecanu L, Papadopoulos V. Novel androstenetriol interacts with the mitochondrial translocator protein and controls steroidogenesis. J Biol Chem 2011; 286:9875–9887.
  57. 57. Qi X, Xu J, Wang F, Xiao J. Translocator protein (18 kDa): a promising therapeutic target and diagnostic tool for cardiovascular diseases. Oxid Med Cell Longev 2012; 2012:162934.
  58. 58. Veenman L, Gavish M, Kugler W. Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment. Anticancer Agents Med Chem 2014; 14:559–577.
  59. 59. Waterfield JD, McGeer EG, McGeer PL. The peripheral benzodiazepine receptor ligand PK 11195 inhibits arthritis in the MRL-lpr mouse model. Rheumatology (Oxford) 1999; 38:1068–1073.
  60. 60. Zeno S, Zaaroor M, Leschiner S, Veenman L, Gavish M. CoCl(2) induces apoptosis via the 18 kDa translocator protein in U118MG human glioblastoma cells. Biochemistry 2009; 48:4652–4661.
  61. 61. Veenman L, Vainshtein A, Gavish M. TSPO as a target for treatments of diseases, including neuropathological disorders. Cell Death Dis 2015.
  62. 62. Vainshtein A, Veenman L, Shterenberg A, et al. Quinazoline-based tricyclic compounds that regulate programmed cell death, induce neuronal differentiation, and are curative in animal models for excitotoxicity and hereditary brain disease. Cell Death Discovery 2015; 1.
  63. 63. Veiga S, Carrero P, Pernia O, Azcoitia I, Garcia-Segura LM. Translocator protein 18 kDa is involved in the regulation of reactive gliosis. Glia 2007; 55:1426–1436.
  64. 64. Torres SR, Frode TS, Nardi GM, et al. Anti-inflammatory effects of peripheral benzodiazepine receptor ligands in two mouse models of inflammation. Eur J Pharmacol 2000; 408:199–211.
  65. 65. Bribes E, Bourrie B, Casellas P. Ligands of the peripheral benzodiazepine receptor have therapeutic effects in pneumopathies in vivo. Immunol Lett 2003; 88:241–247.
  66. 66. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004; 24:1006–1014.
  67. 67. Olson JM, Ciliax BJ, Mancini WR, Young AB. Presence of peripheral-type benzodiazepine binding sites on human erythrocyte membranes. Eur J Pharmacol 1988; 152:47–53.
  68. 68. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248–254.
  69. 69. Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem 1996; 236:302–308.
  70. 70. Awad M, Gavish M. Solubilization of peripheral-type benzodiazepine binding sites from cat cerebral cortex. J Neurochem 1989; 52:1880–1885.
  71. 71. Danovich L, Veenman L, Leschiner S, et al. The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur Neuropsychopharmacol 2008; 18:24–33.
  72. 72. Goldstein JL, Brown MS. The LDL receptor. Arterioscler, Thromb Vasc Biol 2009; 29:431–438.
  73. 73. Fujimura Y, Hwang PM, Trout Iii H, et al. Increased peripheral benzodiazepine receptors in arterial plaque of patients with atherosclerosis: an autoradiographic study with [(3)H]PK 11195. Atherosclerosis 2008; 201:108–111.
  74. 74. Gaemperli O, Shalhoub J, Owen DR, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J 2012; 33:1902–1910.
  75. 75. de Lima CB, Tamura EK, Montero-Melendez T, et al. Actions of translocator protein ligands on neutrophil adhesion and motility induced by G-protein coupled receptor signaling. Biochem Biophys Res Commun 2012; 417:918–923.
  76. 76. de Bont N, Netea MG, Demacker PN, Kullberg BJ, van der Meer JW, Stalenhoef AF. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur J Clin Invest 2000; 30:818–822.
  77. 77. Benavides J, Malgouris C, Imbault F, et al. "Peripheral type" benzodiazepine binding sites in rat adrenals: binding studies with [3H]PK 11195 and autoradiographic localization. Arch Int Pharmacodyn Ther 1983; 266:38–49.
  78. 78. Canat X, Guillaumont A, Bouaboula M, et al. Peripheral benzodiazepine receptor modulation with phagocyte differentiation. Biochem Pharmacol 1993; 46:551–554.
  79. 79. Gavish M, Bachman I, Shoukrun R, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 1999; 51:629–650.
  80. 80. Martini C, Chelli B, Betti L, et al. Peripheral benzodiazepine binding sites in platelets of patients affected by mitochondrial diseases and large scale mitochondrial DNA rearrangements. Mol Med 2002; 8:841–846.
  81. 81. Nakamura K, Fukunishi I, Nakamoto Y, Iwahashi K, Yoshii M. Peripheral-type benzodiazepine receptors on platelets are correlated with the degrees of anxiety in normal human subjects. Psychopharmacology 2002; 162:301–303.
  82. 82. Fan J, Rone MB, Papadopoulos V. Translocator protein 2 is involved in cholesterol redistribution during erythropoiesis. J Biol Chem 2009; 284:30484–30497.
  83. 83. Bode J, Veenman L, Vainshtein A, Kugler W, Rosenberg BJ, Gavish M. Modulation of gene expression associated with the cell cycle and tumorigenicity of glioblastoma cells by the 18 kDa translocator protein (TSPO). Austin J Pharmacol Ther 2014; 2.
  84. 84. Veenman L, Bode J, Gaitner M, et al. Effects of 18-kDa translocator protein knockdown on gene expression of glutamate receptors, transporters, and metabolism, and on cell viability affected by glutamate. Pharmacogenet Genomics 2012; 22:606–619.
  85. 85. Stivala S, Reiner MF, Lohmann C, Luscher TF, Matter CM, Beer JH. Dietary alpha-linolenic acid increases the platelet count in ApoE–/– mice by reducing clearance. Blood 2013; 122:1026–1033.
  86. 86. Nishikawa H, Hayashi H, Kubo S, Tsubota-Matsunami M, Sekiguchi F, Kawabata A. Inhibition by hydrogen sulfide of rabbit platelet aggregation and calcium mobilization. Biol Pharm Bull 2013; 36:1278–1282.
  87. 87. Shargorodsky L, Veenman L, Caballero B, et al. The nitric oxide donor sodium nitroprusside requires the 18 kDa translocator protein to induce cell death. Apoptosis 2012; 17:647–665.
  88. 88. Giatti S, Pesaresi M, Cavaletti G, et al. Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience 2009; 164:520–529.
  89. 89. Giannaccini G, Betti L, Palego L, et al. Serotonin transporter (SERT) and translocator protein (TSPO) expression in the obese ob/ob mouse. BMC Neurosci 2011; 12:18.
  90. 90. Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol 2009; 219:53–57.
  91. 91. Veenman L, Gavish M. Peripheral-type benzodiazepine receptors: their implication in brain disease. Drug Development Research 2000; 50:355–370.

Written By

Jasmina Dimitrova-Shumkovska, Leo Veenman, Inbar Roim, Svetlana Leschiner and Moshe Gavish

Submitted: March 16th, 2015 Reviewed: November 9th, 2015 Published: December 2nd, 2015